Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentric, Prospective, Non-Interventional Long-Term Registry Study to Describe the Safety and Importance of Gilenya (Fingolimod 05.mg) in the Treatment of Multiple Sclerosis Patients

Trial Profile

Multicentric, Prospective, Non-Interventional Long-Term Registry Study to Describe the Safety and Importance of Gilenya (Fingolimod 05.mg) in the Treatment of Multiple Sclerosis Patients

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PANGAEA
  • Sponsors Novartis
  • Most Recent Events

    • 12 Oct 2018 Interim results (n=77) assessing efficacy of fingolimod in two subgroups of young adult less than 20 and 30 years of age presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 Interim results assessing treatment effectiveness of fingolimod in relapsing remitting multiple sclerosis patients treated for 5 years in clinical practice, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 Interim results on the safety of fingolimod and persistency of patients treated with fingolimod for up to 5 years in daily clinical practice in Germany presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top